Reference

Direct injection, column switching-liquid chromatographic technique for the estimation of rabeprazole in bioequivalence study

Direct injection, column switching-liquid chromatographic technique for the estimation of rabeprazole in bioequivalence study. Singh, Sonu Sundd; Jain, Manish; Shah, Hiten; Gupta, Sapna; Thakker, Purav; Shah, Ruchy; Lohray, Braj Bhushan (Zydus Research Centre, Ahmedabad 382213, India). Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences, 813(1-2), 247-254 (English) 2004 Elsevier B.V. CODEN: JCBAAI. ISSN: 1570-0232. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) A rapid, simple and sensitive high-performance liq. chromatog.-ultra violet (HPLC-UV) method with column switching between sample pretreatment column and anal. column was developed for the quantitation of rabeprazole in human plasma; on a Bio-Sample Anal. system (Cosense for BA) from Shimadzu Corporation, Kyoto, Japan. Zaleplon was used as an internal std.Some commonly used reagents like 117976-90-6 is used in this experiment. The method was validated as per USFDA guidelines for the concn. range of 20.0-1200.0 ng/mL and the correlation coeff. were found to be better than 0.999. Recovery of rabeprazole as well as the internal std. from human plasma was more than 90.0%. Rabeprazole was stable in human plasma for 4 mo at -70±5° and for 20.0 h at ambient temp. In the auto sampler, the drug was stable for 24.0 h at 4°. The method was specific as there were no interfering peaks in the human plasma eluting at the retention times of the rabeprazole and the internal std. The frozen plasma samples contg. rabeprazole were stable to three freeze thaw cycles. The bioanal. method was rugged in terms of inter- and intraday accuracy and precision. The method was simple, specific, sensitive, precise, accurate and suitable for bioequivalence and pharmacokinetic studies. It was successfully applied to the pilot bioequivalence study of 20 mg rabeprazole tablet of German Remedies Ltd. (a division of Cadila Healthcare Ltd.), India vs. Pariet tablet of Eisai Ltd. & Janssen-Cilag Ltd., Japan in male human subjects. .

Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism

All Rights Reserved. Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism. Ariizumi, Ken; Ohara, Shuichi; Koike, Tomoyuki; Inomata, Yoshifumi; Iijima, Katsunori; Sekine, Hitoshi; Noguchi, Mitsunori; Sugiyama, Koichi; Eda, Yoshiki; Kayaba, Shoichi; Kawamura, Msashi; Shimosegawa, Tooru (Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan). Journal of Gastroenterology and Hepatology, 21(9), 1428-1434 (English) 2006 Blackwell Publishing Asia Pty Ltd. CODEN: JGHEEO. ISSN: 0815-9319. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Background: The acid suppressive effects of omeprazole (OPZ) and lansoprazole (LPZ) are influenced by the CYP2C19 polymorphism. On the other hand, some investigators have reported that acid suppressive effect of rabeprazole (RPZ) was not significantly affected by CYP2C19. The present study was designed to investigate whether the CYP2C19 genotype is related to the healing of reflux esophagitis (RE) in treatment with RPZ 10 mg. Methods: One hundred and three Japanese patients with RE were treated with daily oral administration of 10 mg RPZ. At 4 and 8 wk after the start of treatment, healing of RE was evaluated endoscopically.In this article, certain chemicals are used. Some of their cas registry numbers are 92228-49-4 and 117976-90-6 The CYP2C19 genotype was investigated before the treatment. Results: At 4 wk after the start of treatment, the healing rates for homo-extensive metabolizer, hetero-extensive metabolizer, and poor metabolizer patients were 86.1% (31/36), 92.0% (46/50), and 82.4% (14/17), resp., and at 8 wk after the start of treatment, the healing rates were 86.1% (31/36), 92.0% (46/50), and 82.4% (14/17), resp. There were no significant differences in the healing rate of RE among the three genotypes at either 4 or 8 wk after the start of treatment. Conclusions: The therapeutic effects of 10mg/day RPZ administration on RE may be uninfluenced by the CYP2C19 polymorphism. .